<div id="readability-page-1"><div id="article-body-8557291"><div><p>Big pharma just got another nudge from Washington that Medicare pricing pressure is only moving in one direction. A new batch of well-known drugs from Pfizer (PFE, Financial), Novartis (NVS, Financial), and Eli Lilly (LLY, Financial) has been pulled into the next round of Medicare price negotiations.</p><p>The Centers for Medicare &amp; Medicaid Services added 15 drugs to its latest negotiation list, including Pfizer's Xeljanz, Novartis' Cosentyx, and Lilly's Trulicity. Other familiar names made the cut too, like AbbVie's Botox, Bristol Myers Squibb's Orencia, and Gilead's Biktarvy. These aren't niche therapies. Between November 2024 and October 2025, about 1.8 million Medicare beneficiaries used the drugs on the list, driving roughly $27 billion in prescription spending.</p><p>The key thing to remember is timing. Any negotiated prices won't take effect until 2028, so there's no immediate hit to revenue. But the signal is hard to miss. Medicare is zeroing in on large, established drugs that generate steady cash, and that puts long-term pricing pressure on some of pharma's most dependable products.</p></div></div></div>

ELIL

LLYZ

LLYX

ELIS

<p>Big pharma faces new pricing pressures as Medicare adds 15 well-known drugs to its negotiation list, including Pfizer's Xeljanz and Novartis' Cosentyx. These drugs, used by 1.8 million Medicare beneficiaries, account for $27 billion in spending. While negotiated prices won't take effect until 2028, the move signals long-term pricing pressure on established drugs, impacting revenue for major companies like Pfizer, Novartis, and Eli Lilly.</p>

- The Centers for Medicare & Medicaid Services has included 15 well-known drugs from Pfizer, Novartis, and Eli Lilly in its latest round of Medicare price negotiations.  
- These drugs, widely used by Medicare beneficiaries and driving significant prescription spending, signal a focused effort by Medicare to apply pricing pressure on established pharmaceutical products.  
- While negotiated prices will not take effect until 2028, the move indicates a long-term challenge for big pharma regarding the pricing of their major drugs.

Some of Pharma's Biggest Brands Face a New Reality (Status: Pending)